Medi-Macro (Human Albumin As Macroaggregates)

Human Albumin As Macroaggregates consist of tiny albumin particles that, after intravenous injection, become trapped in the pulmonary capillaries. Their radioactivity creates a detectable signal on gamma cameras, allowing clinicians to map lung perfusion patterns.

The dose of Medi-Macro is determined by the prescribing physician or nuclear medicine specialist based on the specific imaging protocol, patient characteristics, and the required radiotracer activity. No fixed dosing regimen is provided here.

Safety data for Medi-Macro in pregnancy and lactation are limited. The product should only be used if the potential diagnostic benefit outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Medi-Macro, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

Medi-Macro uses human albumin macroaggregates, which are widely accepted for their predictable pulmonary capillary lodging and high imaging quality. Alternative agents may use different protein carriers or particle sizes, but the clinical performance of Medi-Macro is comparable to other FDA‑ or EMA‑approved perfusion tracers.

Medi-Macro must be stored at 2‑8 °C in its original packaging, protected from light. It should not be frozen or shaken, and any unused portion should be discarded according to local regulations after the recommended storage period.

Medi-Macro is supplied as a sterile solution for injection and is administered intravenously by a qualified healthcare professional. The injection is performed under aseptic conditions, typically as a rapid bolus, followed by immediate imaging.

The most serious risks include anaphylactic reactions, pulmonary embolism due to macroaggregate lodging, and severe hypotension. Patients should be monitored closely during and after administration, and emergency measures should be readily available.

Medi-Macro should not be used in individuals with known hypersensitivity to human albumin, severe pulmonary hypertension, or those for whom the diagnostic benefit does not outweigh the potential risks. The decision must be made by the treating physician.